Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

1. www.sciencedirect.com › science › articleType II diabetes mellitus: a review on recent drug based...

   www.sciencedirect.com › science › article

   1 Νοε 2020 · The major drug therapy for type II DM comprises of insulin secretagogues, biguanides, insulin sensitizers, alpha glucosidase inhibitors, incretin mimetics, amylin antagonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors.

   • Nanoparticulate-Based Drug Delivery Systems for Small Molecule Anti-Diabetic Drugs

     The global prevalence of diabetes mellitus (DM) is rapidly...

   • Epidemiological Perspective

     In diabetes mellitus, the transporter, GIuT4 is reduced. ......

   • Type 1 and 2 Diabetes Mellitus

     Type 1 and 2 diabetes mellitus: A review on current...

   • Potential of Insulin Nanoparticle Formulations for Oral Delivery and Diabetes Treatment

     Diabetes mellitus is one of the most prevalent metabolic and...

   • Perspectives on The Past, Present, and Future

     The importance of insulin resistance and β-cell dysfunction...

   • Battle of Glp-1 Delivery Technologies

     Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) belong...

   • An 8-Month Prospective Study

     Another study also showed that exenatide improves diastolic...

2. www.nejm.org › doi › fullTirzepatide versus Semaglutide Once Weekly in Patients with Type...

   www.nejm.org › doi › full

   25 Ιουν 2021 · Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The...

3. www.nejm.org › doi › fullGlycemia Reduction in Type 2 Diabetes — Glycemic Outcomes

   www.nejm.org › doi › full

   21 Σεπ 2022 · The comparative effectiveness of glucose-lowering medications for use with metformin to maintain target glycated hemoglobin levels in persons with type 2 diabetes is uncertain. In this trial...

4. pubmed.ncbi.nlm.nih.gov › 32598218Comparative Effectiveness of Glucose-Lowering Drugs for Type 2...

   pubmed.ncbi.nlm.nih.gov › 32598218

   18 Αυγ 2020 · Study selection: English-language randomized trials that had at least 24 weeks of intervention and assessed the effects of glucose-lowering drugs on mortality, glycemic, and vascular outcomes. Data extraction: Pairs of reviewers extracted data and appraised risk of bias.

5. pmc.ncbi.nlm.nih.gov › articles › PMC7221535Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs - PMC

   pmc.ncbi.nlm.nih.gov › articles › PMC7221535

   Since type 2 diabetes mellitus (T2DM) is suffered by the majority of diabetic patients (around 90–95%) and often the mono-target therapy fails in managing blood glucose levels and the other comorbidities, this review focuses on the potential drugs acting on multi-targets involved in the treatment of this type of diabetes.

6. www.nature.com › articles › nrendoPharmacology and therapeutic implications of current drugs for...

   www.nature.com › articles › nrendo

   24 Ιουν 2016 · Type 2 diabetes mellitus (T2DM) is a global epidemic that poses a major challenge to health-care systems. Improving metabolic control to approach normal glycaemia (where practical) greatly...

7. www.nature.com › articles › s41574/021/00489-yNovel therapies with precision mechanisms for type 2 diabetes...

   www.nature.com › articles › s41574/021/00489-y

   4 Μαΐ 2021 · Drugs in development for T2DM must show meaningful reductions in glycaemic parameters as well as cardiovascular safety. Results from an increasing number of cardiovascular outcome trials...